Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2013

01-05-2013 | Preclinical study

Characteristics of basal cytokeratin expression in breast cancer

Authors: Alaa T. Alshareeda, Daniele Soria, Jonathan M. Garibaldi, Emad Rakha, Christopher Nolan, Ian O. Ellis, Andrew R. Green

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

Breast cancer is recognised to be a heterogeneous disease and the second most common cause of morbidity and mortality worldwide in women. Basal-like breast cancer (BLBC) is associated with aggressive characteristics including development of recurrent disease and reduced survival. BLBC has been defined in some studies as tumours lacking both oestrogen receptor and progesterone receptor protein expression. Gene expression studies have shown that these tumours are also associated with expression of basal-type cytokeratins, the phenotypic patterns of basal cytokeratin expression in BLBC have not been widely studied. A well-characterised series of 995 invasive breast cancers with a long-term follow up were investigated using immunohistochemical staining for four basal cytokeratins (CK5, CK5/6, CK14 and CK17). The data were analysed using univariate and clustering analysis. As a result BLBC, as defined by negativity for ER and HER2 showed variable positivity for basal cytokeratin expression: 61.7 % CK5, 50.5 % CK5/6, 24.2 % CK14 and 23 % CK17. These characteristics were associated with poor outcome characteristics including high histological grade, mitosis, pleomorphism and tumour size >1.5 cm. CK5 positivity was more associated with ER, PgR, TN and double ERPgR, than the other cytokeratins. Four different clusters of basal cytokeratin expression patterns were identified: (1) negativity for all basal cytokeratins, (2) CK5+/CK17, (3) CK5/CK17+ and (4) CK5+/CK17+. These patterns of basal cytokeratin expression associated with differences in patient outcome, clusters 1 and 3 showed better outcomes than cluster 4 and 2, with cluster 2 having the poorest prognosis. In conclusion, four basal cytokeratin expression patterns were identified in human breast cancer using unsupervised clustering analysis and these patterns are associated with differences in patient outcome.
Literature
1.
go back to reference Bhargava R et al (2008) CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma. Am J Clin Pathol 130(5):724–730PubMedCrossRef Bhargava R et al (2008) CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma. Am J Clin Pathol 130(5):724–730PubMedCrossRef
2.
go back to reference Altmannsberger M et al (1986) Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol 51(3):265–275PubMedCrossRef Altmannsberger M et al (1986) Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol 51(3):265–275PubMedCrossRef
3.
go back to reference Dairkee SH et al (1987) Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 10(1):11–20PubMedCrossRef Dairkee SH et al (1987) Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 10(1):11–20PubMedCrossRef
4.
go back to reference Moll R et al (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31(1):11–24PubMedCrossRef Moll R et al (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31(1):11–24PubMedCrossRef
5.
go back to reference Nagle RB et al (1986) Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34(7):869–881PubMedCrossRef Nagle RB et al (1986) Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34(7):869–881PubMedCrossRef
6.
go back to reference Millikan RC et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef Millikan RC et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef
7.
go back to reference Gusterson BA et al (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7(4):143–148PubMedCrossRef Gusterson BA et al (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7(4):143–148PubMedCrossRef
8.
go back to reference Malzahn K et al (1998) Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433(2):119–129PubMedCrossRef Malzahn K et al (1998) Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433(2):119–129PubMedCrossRef
9.
go back to reference Paredes J et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450(1):73–80PubMedCrossRef Paredes J et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450(1):73–80PubMedCrossRef
10.
go back to reference Ribeiro-Silva A et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47(5):458–466PubMedCrossRef Ribeiro-Silva A et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47(5):458–466PubMedCrossRef
11.
go back to reference Parry S et al (2008) Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 61(9):1045–1050PubMedCrossRef Parry S et al (2008) Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 61(9):1045–1050PubMedCrossRef
12.
go back to reference Nalwoga H et al (2008) Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS 116(6):515–525PubMedCrossRef Nalwoga H et al (2008) Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS 116(6):515–525PubMedCrossRef
13.
go back to reference Rodriguez-Pinilla SM et al (2007) Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60(9):1006–1012PubMedCrossRef Rodriguez-Pinilla SM et al (2007) Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60(9):1006–1012PubMedCrossRef
14.
go back to reference Ding Y, Ruan Q (2006) The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technol Med Sci 26(4):405–407PubMedCrossRef Ding Y, Ruan Q (2006) The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technol Med Sci 26(4):405–407PubMedCrossRef
15.
go back to reference Kordek R et al (2010) Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 29:39PubMedCrossRef Kordek R et al (2010) Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 29:39PubMedCrossRef
16.
17.
go back to reference Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205–262PubMed Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205–262PubMed
18.
go back to reference Rakha EA et al (2009) Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 113(3):411–422PubMedCrossRef Rakha EA et al (2009) Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 113(3):411–422PubMedCrossRef
19.
go back to reference Madjd Z et al (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200(5):633–639PubMedCrossRef Madjd Z et al (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200(5):633–639PubMedCrossRef
20.
go back to reference Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568–2581PubMedCrossRef Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568–2581PubMedCrossRef
21.
go back to reference Alshareeda AT et al (2012) Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Res Treat 134(2):519–529PubMedCrossRef Alshareeda AT et al (2012) Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Res Treat 134(2):519–529PubMedCrossRef
22.
go back to reference Garc T et al (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:472–480CrossRef Garc T et al (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:472–480CrossRef
23.
go back to reference Aleskandarany MA et al (2011) Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res 14(1):R3CrossRef Aleskandarany MA et al (2011) Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res 14(1):R3CrossRef
24.
go back to reference Soria D et al (2010) A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 40(3):318–330PubMedCrossRef Soria D et al (2010) A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 40(3):318–330PubMedCrossRef
25.
go back to reference Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef
26.
go back to reference Rakha EA et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156PubMedCrossRef Rakha EA et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156PubMedCrossRef
27.
go back to reference Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502PubMedCrossRef Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502PubMedCrossRef
28.
go back to reference Nielsen TO et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374PubMedCrossRef Nielsen TO et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374PubMedCrossRef
29.
go back to reference Mohammadizadeh F et al (2009) Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. Indian J Med Sci 63(4):152–162PubMedCrossRef Mohammadizadeh F et al (2009) Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. Indian J Med Sci 63(4):152–162PubMedCrossRef
30.
go back to reference Eerola H et al (2008) Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 10(1):R17PubMedCrossRef Eerola H et al (2008) Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 10(1):R17PubMedCrossRef
31.
go back to reference Bocker W et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737–746PubMed Bocker W et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737–746PubMed
32.
go back to reference Fulford LG et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4PubMedCrossRef Fulford LG et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4PubMedCrossRef
33.
go back to reference Rouzier R et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685PubMedCrossRef Rouzier R et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685PubMedCrossRef
34.
go back to reference Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310PubMedCrossRef Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310PubMedCrossRef
35.
go back to reference Fuqua SA et al (1993) The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 26(2):191–202PubMedCrossRef Fuqua SA et al (1993) The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 26(2):191–202PubMedCrossRef
36.
go back to reference Potemski P et al (2005) Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69(6):478–485PubMedCrossRef Potemski P et al (2005) Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69(6):478–485PubMedCrossRef
37.
go back to reference Cheang MC et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376PubMedCrossRef Cheang MC et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376PubMedCrossRef
38.
go back to reference Bertucci F et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123(1):236–240PubMedCrossRef Bertucci F et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123(1):236–240PubMedCrossRef
39.
go back to reference Calza S et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8(4):R34PubMedCrossRef Calza S et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8(4):R34PubMedCrossRef
40.
go back to reference Yang XR et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef Yang XR et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef
Metadata
Title
Characteristics of basal cytokeratin expression in breast cancer
Authors
Alaa T. Alshareeda
Daniele Soria
Jonathan M. Garibaldi
Emad Rakha
Christopher Nolan
Ian O. Ellis
Andrew R. Green
Publication date
01-05-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2518-x

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine